Evidence map›Paper›PMID 33520346›Full record

ArticleACS catalysis2020

Catalytic Mechanism of Non-Target DNA Cleavage in CRISPR-Cas9 Revealed by

Lorenzo Casalino, Łukasz Nierzwicki, Martin Jinek, Giulia Palermo

Abstract read
In one paragraph

Article in ACS catalysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Controlled dynamic remodeling of the spliceosome active site enables the first step of splicing.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Engineering Cas9: next generation of genomic editors.Applied microbiology and biotechnology · 2024
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lorenzo CasalinoDepartment of Chemistry and Biochemistry, University of California San Diego, La Jolla, California 92093, United States.ORCID 0000-0003-3581-1148
Łukasz NierzwickiDepartment of Bioengineering, University of California Riverside, Riverside, California 92521, United States.
Martin JinekDepartment of Biochemistry, University of Zürich, CH-8057 Zürich, Switzerland.
Giulia PalermoDepartment of Bioengineering and Department of Chemistry, University of California Riverside, Riverside, California 92521, United States.ORCID 0000-0003-1404-8737

Funding

Discovery of Biomarkers for Age-Related Macular DegenerationR01EY027440 · NEI · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI VULLEV, VALENTINE · 2017 to 2020
$1.5M
NEI NIH HHS R01 EY027440
6 · The paper itself

Abstract

CRISPR-Cas9 is a cutting-edge genome editing technology, which uses the endonuclease Cas9 to introduce mutations at desired sites of the genome. This revolutionary tool is promising to treat a myriad of human genetic diseases. Nevertheless, the molecular basis of DNA cleavage, which is a fundamental step for genome editing, has not been established. Here, quantum-classical molecular dynamics (MD) and free energy methods are used to disclose the two-metal-dependent mechanism of phosphodiester bond cleavage in CRISPR-Cas9.

Indexed as

CRISPR-Cas9free energy simulationsgenome editingmagnesium-aided catalysisnon-coding RNAphosphodiester bond cleavageprotein/nucleic acid interactionsQM/MM

Identifiers

PMID33520346
PMCPMC7842700

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.